Adaptive Biotechnologies And Microsoft Launch Virtual Immunerace Study To Inform Novel COVID-19 Diagnostics To Address Unmet Needs In Testing
Microsoft News, May 5th, 2020
May 5, 2020,
Volume 266, Issue 1
LabCorp, through its Covance drug development business, will provide a safe, in-person COVID-19 sample collection service from the convenience of patients' homes
De-identified data about immune response to COVID-19 will be made freely available to advance public health solutions
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced it has begun enrolling a virtual clinical study, ImmuneRACE, as part of a broader effort it has undertaken with Microsoft Corp. (Nasdaq: MSFT) to rapidly map and measure the immune response to the COVID-19 virus to inform improved diagnostics to fulfill the need for more reliable testing...
Read More ...
Other articles in the Microsoft News section of Volume 266, Issue 1:
See all archived articles in the Microsoft News section.
- Adaptive Biotechnologies And Microsoft Launch Virtual Immunerace Study To Inform Novel COVID-19 Diagnostics To Address Unmet Needs In Testing